<DOC>
	<DOCNO>NCT01698814</DOCNO>
	<brief_summary>The purpose study evaluate ocular safety investigational ophthalmic solution subject 2 year age old asymptomatic eye administer daily eye 6 week .</brief_summary>
	<brief_title>A Six-Week Safety Study Investigational Ophthalmic Solution</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<criteria>Able willing comply study protocol follow protocol instruction . Adequate birth control method duration study . Bestcorrected visual acuity ( BCVA ) 55 great eye . Willing avoid contact lens wear study visit ; contact lens wear also stable consistent 1 month prior Visit 1 expect remain study duration . Willing able sign Informed Consent form . Other protocolspecified inclusion criterion may apply . Women childbearing potential pregnant , breastfeeding , agreement use adequate birth control method prevent pregnancy throughout study . Evidence contact lens care solution relate ocular surface damage giant papillary conjunctivitis ( GPC ) . Any ocular infection ( bacterial , viral fungal ) history ocular Herpes ( simplex zoster ) adenoviral infection either eye ocular infection within 30 day prior Visit 1 . Using systemic medication ( ) chronic dose regimen less 30 day change dosage medication within 30 day prior Visit 1 . Current past history glaucoma ocular hypertension . History retinal detachment , diabetic retinopathy , progressive retinal disease . Presence ocular condition may affect study outcome . Corneal condition affect corneal structure . History evidence ocular surgical procedure within 1 year prior Visit 1 . Current recent medical condition , opinion Investigator , would preclude safe participation study . Prior , current , anticipated use ophthalmic agent investigational product study participation . Participation investigational study within 30 day prior Visit 1 concomitantly study . Known contraindication hypersensitivity study medication component . Other protocolspecified exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>ocular safety</keyword>
	<keyword>allergic conjunctivitis</keyword>
</DOC>